HLA-DRA (9.3 ± 0.1; 31-fold increase) and CD74 (Mean ± SEM = 10.94 ± 0.08; 21.8-fold) exhibited the most significant increase in expression levels in tumor tissue relative to normal tissue, suggesting its potential use as a biomarker for PDAC prognosis, whereby PDAC patients with low levels of CD74 or HLA-DRA would benefit from TGFB2 mRNA knockdown. This evidence concerns the gene HLA-DRA and neoplasm.